Biotest
22
2
2
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
22.7%
5 terminated/withdrawn out of 22 trials
75.0%
-11.5% vs industry average
36%
8 trials in Phase 3/4
40%
6 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Role: lead
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Role: collaborator
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
Role: collaborator
Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins
Role: collaborator
Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
Role: lead
Adjusted Fibrinogen Replacement Strategy
Role: lead
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
Role: lead
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
Role: lead
Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
Role: collaborator
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
Role: lead
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
Role: lead
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
Role: lead
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)
Role: lead
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Role: collaborator
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
Role: collaborator
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
Role: lead
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
Role: lead
A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant
Role: lead
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Role: lead
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Role: collaborator